Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Pleomorphic Liposarcoma: Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Pleomorphic Liposarcoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Pleomorphic Liposarcoma

Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Leiomyosarcoma: Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Leiomyosarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Leiomyosarcoma

Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase II for Cutaneous Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Cutaneous Squamous Cell Carcinoma (cSCC)

Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Round Cell Liposarcoma: Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Round Cell Liposarcoma....

Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Myxoid Liposarcoma: Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Myxoid Liposarcoma. According...

Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Dedifferentiated Liposarcoma: Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Dedifferentiated Liposarcoma. According...

Data Insights

(Cisplatin + vinblastine sulphate) by Intensity Therapeutics for Soft Tissue Sarcoma: Likelihood of Approval

(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase III for Soft Tissue Sarcoma....